Navigation Links
Ganeden Biotech Announces Grants for Early Investigators to Research Probiotic GanedenBC30
Date:9/30/2009

CLEVELAND, Sept. 30 /PRNewswire/ -- Ganeden Biotech Inc., makers of the patented probiotic strain GanedenBC30® (Bacillus coagulans GBI-30, 6086), today announced two grants for early investigators. Grants focus on researching the effects of GanedenBC30 on human immune cells. Previous studies have demonstrated the ability of GanedenBC30 to modulate numerous human immune cells, both in vitro and in vivo.

To be eligible, investigators must have a full-time faculty appointment at a research institution or medical school. Applicants must have interest in studying the effects of GanedenBC30 on human immune cells, as well as the capacity to conduct such research.

Two grants will be funded at a maximum of $15,000 for each project. Applicants will be expected to submit a budget outlining how the funds will be used. A meeting with Ganeden's Scientific Board will be required prior to the start of the research, as well as following the research to present the results. Travel for these meetings will be subsidized above the grant amount.

Applications will be reviewed by:

  • Ken Alibek, CEO, AFG Bioscience
  • John Endres, chief scientific officer, AIBMR Life Sciences
  • Sean Farmer, chief scientific officer, Ganeden Biotech
  • Glenn Gibson, professor, University of Reading
  • Gary Huffnagle, professor, University of Michigan
  • David Keller, vice president of scientific operations, Ganeden Biotech

Grant applications will be judged on quality of the proposed experimental design, originality of the proposal, evidence of the applicant's ability to conduct the proposed research, and relevance of the proposed research to the health of the general population.

Please contact Dr. David Keller at keller@ganedenbiotech.com for all request
'/>"/>

SOURCE Ganeden Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Melanoma Cancer Clinical Trial
2. Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC
3. Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
4. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
5. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
6. Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
7. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
8. Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse
9. PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies
10. Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
11. Researchers at Axial Biotech Develop a DNA Test for Scoliosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Research and Markets ... the "Investigation Report on China,s Latanoprost Market, ... Developed by Pharmacia & Upjohn in 1995, latanoprost ... reduces intraocular pressure. As the first pressure- lowering ... name of Xalatan) entered China ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015  Perrigo Company ... that it has completed the acquisition of leading OTC ... at €200 million. The transaction is a clear demonstration ... the Company,s leading European distribution network spanning 36 countries.  ... Joseph C. Papa commented, "We are excited to ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de 2015 ... anunció hoy su participación en el  Congreso de ... soluciones cardiológicas más recientes y novedosas, entre ellas ... conectan a las personas y la tecnología con ... a diagnosticar, guiar los tratamientos y permitir atención ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach on solutions ... it should begin with the employer and employees getting together for meaningful group ...
(Date:8/28/2015)... ... ... Gregory K. Toumayan, D.C., Q.M.E., is now treating patients with back pain and associated ... pain, stiffness, muscle spasms, and numbness. , Dr. Toumayan received his Bachelor of ... earn his title of Doctor of Chiropractic from the Palmer College of Chiropractic and ...
(Date:8/28/2015)... ... ... Mendon, IL, home of the Adams County Fairgrounds, was treated once again to ... In its second year, the “Music With A Mission” benefit concert was held there ... “Music With A Mission” is to raise money to help fund music education programs ...
(Date:8/28/2015)... , ... August 28, 2015 , ... The newest therapy ... be available for general use any time soon, according to educational website Surviving Mesothelioma. ... therapy that received orphan drug designation for mesothelioma last week from the FDA, will ...
(Date:8/28/2015)... ... August 28, 2015 , ... External Counterpulsation, also known as ... is now selling External Counterpulsation (EECP or ECP) machines with a full clinic licence ... been in business since 2007 helping people prevent and reverse heart disease ...
Breaking Medicine News(10 mins):Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2
... associated with age, might affect women with diabetes or ... recent study .// ,The study shows elderly ... and are at an increased risk for developing cognitive ... women with pre-diabetes or diabetes was increased nearly two-fold. ...
... say that they have now found out that long-term use ... of cancer.// ,The trial results of the longest follow-up ... show cardiovascular death was reduced by 17 percent and coronary ... drug simvastatin, also known as Zocor, for 10 years compared ...
... 600 babies in the United States is born with an isolated ... cleft only // and no other birth defects. ,Researchers say ... if a couple will have a child born with a cleft ... According to researchers isolated clefts happen during early fetal development. ...
... a degenerative joint disease and one of the oldest ... the joint’s cartilage breaks down and the bones rub ... ,An international, multi-center study shows an effective treatment ... as Prexige. The drug was found to reduces gastric ...
... public places can improve the overall likelihood someone will ... AEDs -- devices capable of shocking the heart back ... 1,000 shopping malls, apartment complexes, and other public places ... volunteers in these communities were then trained in either ...
... recent study researchers say cancer patients who receive treatment have ... new study shows many doctors are not taking the necessary ... more than 100 oncologists to determine if the doctors were ... preventative measures used by the physicians. About 40 percent of ...
Cached Medicine News:
... and Response catheters comprise the world's ... for electrophysiology procedures. Their advanced catheter ... superior torque response with a soft, ... and French sizes, Supreme and Response ...
... Jude Medical's line of guiding introducers ... RAMP, and 2 piece steerable, all ... catheters when the varying curves and ... physician technique. St. Jude Medical guiding ...
Novus 3000 A fully-integrated and powerful 532 nm Operating Room Photocoagulator with reliable DPSS technology and simplified operation using a touch screen interface and remote control....
... provide outstanding insertion performance, with ... high kink resistance and minimal ... sheath cannula provides optimal strength ... an extra strong dilator to ...
Medicine Products: